Neurocrine Biosciences Inc

NASDAQ: NBIX
$133.23
+$0.24 (+0.2%)
Closing price April 17, 2024
Neurocrine Biosciences Inc is a biopharmaceutical company based in San Diego, California, focusing on developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio includes INGREZZA for tardive dyskinesia, ALKINDI for adrenal insufficiency, and several products for conditions like Huntington’s disease, endometriosis, and uterine fibroids. The company is also advancing a range of candidates for conditions such as developmental and epileptic encephalopathy, major depressive disorder, and schizophrenia, among others. Neurocrine Biosciences maintains collaborations with various pharmaceutical companies to enhance its research and development efforts.
Thursday's top analyst upgrades and downgrades included AT&T, Abbott Laboratories, Avis Budget, Bed Bath & Beyond, Beyond Meat, Caterpillar, UPS, Walmart and Wynn Resorts.
The analysts at BofA Securities have made some big changes to the firm's US 1 list of top stock recommendations. FedEx stock was added, and four that have performed admirably were removed.
Thursday's top analysts upgrades and downgrades included Apple, Darden Restaurants, Peloton, Pfizer, Pioneer Natural Resources, Tilray and Zynga.
With rising interest rates, financials and health care look like a great place to be for the next quarter. These five BofA Securities US 1 top stocks look like very solid ideas for growth stock...
Tuesday's top analyst upgrades and downgrades included Avaya, Dell Technologies, On Semiconductor, Neurocrine Biosciences, Palo Alto Networks, Ping Identity, Poshmark and Switch.
A new Stifel research report includes the firm's biotech stock picks for 2021. These five have the biggest upside to the posted price targets and are best suited for patient, aggressive growth...
24/7 Wall St. has been reviewing many sectors for leadership heading into earnings. One area that can offer some defensive strategies is biotech and pharmaceuticals.
Tuesday's top analyst upgrades and downgrades included Charter Communications, Clorox, FirstEnergy, Neurocrine Biosciences, RingCentral, Roku, Seagate Technology, Take-Two Interactive Software and...
Monday's top analyst upgrades and downgrades included Amazon.com, Beyond Meat, Diamondback Energy, Enphase Energy, Groupon, Nuance Communications, PG&E, Spotify and ZoomInfo,
Canaccord Genuity recently released a report detailing some of the biggest biotech catalysts coming out over these next six months.
Tuesday's top analyst upgrades and downgrades included Avaya, Biogen, Broadcom, Chevron, Domino's Pizza, eBay, MGIC Investment, RealReal, Sprout Social, T-Mobile, Zoom Video Communications and Zynga.
24/7 Wall St. found five stocks among Jefferies top U.S. growth calls for this week that look extremely attractive now. They are surviving nicely, with solid results posted and reasonably positive...
The top analyst upgrades, downgrades and initiations for Friday included Adobe, Biogen, Bristol-Myers, Broadcom, Charles Schwab, Ciena, Etsy, Gilead, Oracle, Sarepta, Snap and Wayfair.
Credit Suisse and Merrill Lynch made calls in the biotech and pharmaceutical space last week, ahead of coming earnings reports.
Friday's top analyst upgrades, downgrades and initiations included Agilent Technologies, Alphabet, Altria, Amazon.com, Boeing, Caterpillar, Chipotle Mexican Grill, E*Trade, Gap, Snap and Twitter.